Back to research

Research paper

Assessment of Behavior Abnormalities of Corticosteroids in Children with Nephrotic Syndrome

Prospective pediatric study of 30 children (ages 6-16, mean 9.9 y) with steroid-sensitive idiopathic nephrotic syndrome during a 7-week relapse course. Regimen was ORAL prednisone (2 mg/kg/day tapering to alternate-day ~1.4-1.7 mg/kg by weeks 5-7), not IV pulse. Standardized self-report instruments (CDI, Children Anxiety Scale, Aggression Questionnaire). Anxiety rose from mean 16.2 at baseline to peak 27.9 at week 3, remaining elevated at 22.7 at week 7 (p<0.001). Depression and aggression followed the same peak-at-week-3, still-elevated-at-week-7 pattern. Onset by week 1, peak around week 3, still elevated at week 7.

Indexed context

Soliman NA, et al., (Zagazig University)

nephrotic-syndromepediatriccorticosteroidoral-prednisoneaggressionanxietydepressioncdibehavior-trajectoryweek-3-week-7

Markdown path

content/research/papers/2013-soliman-nephrotic-behavior-abnormalities.md

Findings

Prospective pediatric study of 30 children (ages 6-16, mean 9.9 y) with steroid-sensitive idiopathic nephrotic syndrome during a 7-week relapse course. Regimen was ORAL prednisone (2 mg/kg/day tapering to alternate-day ~1.4-1.7 mg/kg by weeks 5-7), not IV pulse. Standardized self-report instruments (CDI, Children Anxiety Scale, Aggression Questionnaire). Anxiety rose from mean 16.2 at baseline to peak 27.9 at week 3, remaining elevated at 22.7 at week 7 (p<0.001). Depression and aggression followed the same peak-at-week-3, still-elevated-at-week-7 pattern. Onset by week 1, peak around week 3, still elevated at week 7.

Why it may matter for Levi

Closest pediatric study to the specific timeframe Jake and Miki are observing (around 3 weeks in). Demonstrates that in pediatric corticosteroid exposure, behavior symptom scores peak around week 3 and remain elevated through at least week 7. Important caveat - the exposure modality (continuous oral, 7 weeks) is different from Levi's 3-day IV pulse. The parallel is mechanistic (HPA-axis and cytokine dynamics) rather than regimen-matched. Supports the framing that around 3 weeks in is not a strange or unexpected window for pediatric steroid-related behavior changes to peak, even though it does not directly measure single-pulse IVMP behavior outcomes.

Paper text

Soliman et al. (Zagazig, 2013) — Anxiety, depression, and aggression at weeks 1, 3, 5, 7 in pediatric NS

Source

Regimen — important caveat

  • Oral prednisone, not an IV methylprednisolone pulse. Baseline ≤0.5 mg/kg every 48 h (alternate-day). Relapse: 2 mg/kg/day, tapering to ~1.4–1.7 mg/kg alternate-day by weeks 5–7. Duration: 7 weeks of continuous exposure.
  • This means the 7-week trajectory captures mood changes during ongoing oral steroid exposure, not after cessation of a pulse. That matters for extrapolation to Levi.

Key findings

  • Three standardized self-report instruments: Children Depression Inventory (CDI), Children Anxiety Scale, Aggression Questionnaire (physical / verbal / hostility).
  • Assessments at baseline (remission, low-dose or no steroid), then weeks 1, 3, 5, and 7 during relapse treatment.
  • Anxiety: mean 16.2 at baseline → peak 27.9 at week 3 → 22.7 at week 7 (p<0.001).
  • Depression and aggression showed similar progressive elevation, all highly significant, with peak around week 3 and persistence through week 7 with only a slight decline.
  • Pattern: onset by week 1, peak around week 3, still elevated above baseline at week 7.

Limitations relevant to Levi

  • Oral continuous exposure vs. Levi's 3-day IV pulse — the dose-time integral is larger in the Zagazig cohort.
  • Age range 6–16; Levi at 5.5 is below the lower bound.
  • Self-report; Levi is non-verbal so only parent-rated proxy measures would apply.
  • "Starting to appear on week one" in the narrative caption aligns with a within-exposure trajectory, not a post-cessation rebound.

Levi-relevant takeaways

  • Demonstrates that in pediatric corticosteroid exposure, behavior symptoms peak around week 3 and remain elevated through at least week 7 on validated instruments (CDI, anxiety scale, aggression questionnaire). This is the closest pediatric study to the timeframe Jake and Miki are observing, even though the exposure modality differs.
  • Supports the framing that "around 3 weeks in" is not a strange or unexpected time for pediatric steroid-related behavior changes to become most prominent.
  • For an IV pulse rather than ongoing oral therapy, the closest analogue would be the washout / GWS window — so the parallel is mechanistic (HPA-axis and cytokine dynamics) rather than direct.